GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test

GRAL submits final FDA PMA module for the Galleri MCED test, reaching a milestone in broader cancer screening and potential public health impacts.

Zacks Investment Research • Jan 30, 2026

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif., Jan. 29, 2026  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri® multi-cancer early detection (MCED) test.

PRNewsWire • Jan 30, 2026

A Study on Aging Unlocks Holy Grail of Sports Performance

SAN FRANCISCO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Surprisingly, a study of older adults is getting a lot of buzz among peak performance experts in the world of sports. The recent INHANCE neuroimaging study showed for the first time ever that there is an intervention that can upregulate the production of acetylcholine (the “pay attention” brain chemical) — known to downregulate with aging and to plummet in dementia. That intervention is brain exercises in the app BrainHQ from Posit Science. The study made headlines around the globe, garnering attention from experts who work in aging—quickly, and unexpectedly, followed by sports performance experts.

GlobeNewsWire • Jan 26, 2026

Here's Why This Exciting Healthcare Stock Popped 13% Today

The test already has fast-growing commercial sales, and FDA approval would significantly increase them The latest update sees management give upbear guidance for 2026 and confirm an FDA submission in the first quarter of 2026. These 10 Stocks Could Mint the Next Wave of Millionaires ›

The Motley Fool • Jan 22, 2026

GRAIL Inc. - Illumina's Divested Holy Grail

GRAIL (GRAL) offers MCED screening tests that offer employers economic value and employee health clarity. Divestiture of GRAIL by Illumina offers investors $8B valuation foundation. TAM valuation implies substantial upside, assuming eventual FDA approval and moderate market penetration.

Seeking Alpha • Jan 20, 2026

GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026

Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025

In 2025, small-cap stocks underperformed. The Russell 2000 Index tracks the performance of 2,000 U.S. small-cap stocks, delivering a total return of around 13% in 2025.

MarketBeat • Jan 3, 2026

GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif. , Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P.

PRNewsWire • Dec 15, 2025

Here's Why Grail Soared, Again, in November

Early cancer detection is highly beneficial to sufferers, and Grail's Galleri test offers a solution. The company is the leader in the race for FDA approval, but it could benefit from being part of a larger company.

The Motley Fool • Dec 2, 2025

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MENLO PARK, Calif. , Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

PRNewsWire • Dec 1, 2025